苏州纳微科技股份有限公司 股东会议事规则 第一章 总则 第一条 为规范苏州纳微科技股份有限公司（以下简称"公司"）行为，保 证股东会依法行使职权，根据《中华人民共和国公司法》（以下简称"《公司法》"） 《中华人民共和国证券法》《上市公司治理准则》和《上市公司股东会规则》以 及其他法律、行政法规和《苏州纳微科技股份有限公司章程》（以下简称"《公 司章程》"）的规定，制定本规则。 第二条 股东会的召集、提案、通知、召开等事项适用本规则。 第三条 公司应当严格按照法律、行政法规、本规则及公司章程的相关规定 召开股东会，保证股东能够依法行使权利。 公司董事会应当切实履行职责，认真、按时组织股东会。公司全体董事应当 勤勉尽责，确保股东会正常召开和依法行使职权。 第四条 股东会应当在《公司法》和公司章程规定的范围内行使职权。 第五条 股东会分为年度股东会和临时股东会。年度股东会每年召开一次， 应当于上一会计年度结束后的6个月内举行。临时股东会不定期召开，出现下列 情况之一的，公司应当在事实发生之日起2个月内召开临时股东会： （一）董事人数不足《公司法》规定人数或公司章程规定人数的三分之二时； （二）公司未弥补的亏损达实收 ...

苏州纳微科技股份有限公司 内部审计管理制度 第一章 总则 第一条 为了规范苏州纳微科技股份有限公司（以下简称"公司"）的内部审计 工作，提高审计工作质量，实现公司内部审计经常化、制度化，发挥内部审计工作 在促进企业经济管理、提高经济效益中的作用，根据《中华人民共和国审计法》《企 业内部控制基本规范》《上海证券交易所科创板股票上市规则》《上海证券交易所 上市公司内部控制指引》等有关法律、法规、规范性文件的规定，结合公司实际情 况，制定本制度。 第二条 本制度规定了公司内部审计机构及内部审计人员的职责与权限、内部审 计对象与业务范围、内部审计机构工作程序、内部审计档案管理等规范，是公司开 展内部审计管理工作的标准。 本制度所称内部审计，是指由公司内部机构或人员，对其内部控制和风险管理 的有效性、财务信息的真实性和公允性以及经营活动的效率和效果等开展的一种评 价活动。 本制度所称内部控制，是指公司董事会、高级管理人员及其他有关人员为实现 下列目标而提供合理保证的过程：遵守国家法律、法规、规章及其他相关规定；提 高公司经营的效率和效果；保障公司资产的安全；确保公司信息披露的真实、准确、 及时、完整和公平。 第三条本制 ...

Core Insights - The company reported third-quarter revenue of 257 million yuan, representing a year-on-year increase of 22.46% [1] - Net profit for the third quarter was 44.462 million yuan, showing a significant year-on-year growth of 1,558.82% [1] - For the first three quarters, the company achieved revenue of 671 million yuan, which is a year-on-year increase of 22.01% [1] - The net profit for the first three quarters reached 108 million yuan, reflecting a year-on-year growth of 156.56% [1]

Investment Rating - The report maintains a positive outlook on the pharmaceutical sector, indicating an "Overweight" rating for the industry, suggesting it is expected to outperform the overall market [32]. Core Insights - The report highlights that the Shenwan Pharmaceutical and Biological Index increased by 0.6% this week, while the Shanghai Composite Index rose by 2.9% and the Wind All A (excluding financials and petrochemicals) increased by 3.7% [4][6]. - The pharmaceutical sector's overall valuation stands at 30.4 times earnings, ranking 9th among 31 Shenwan primary industries [4][8]. - Significant collaborations and clinical trial results were reported, including a $11.4 billion global strategic partnership between Innovent Biologics and Takeda Pharmaceutical, which includes a $1.2 billion upfront payment [5][13]. - Key clinical trial results presented at the 2025 ESMO conference showed promising outcomes for several drugs, indicating advancements in treatment efficacy for various cancers [14][18][19]. Market Performance - The report details the performance of various sub-sectors within the pharmaceutical industry, with notable increases in medical devices (+0.2%), medical consumables (+1.7%), and medical research outsourcing (+5.5%), while traditional Chinese medicine and other biological products saw declines [4][8]. - The report also notes that 99 A-share pharmaceutical companies released their Q3 2025 earnings, with a total revenue of 94.15 billion yuan, reflecting a 1.3% year-on-year increase [20][22]. Key Events - The report mentions that Bairui Tianheng has passed the Hong Kong Stock Exchange hearing and is in the process of listing its H-shares [12]. - The report emphasizes the importance of the 2025 ESMO conference, where several companies presented significant clinical data, enhancing their market visibility and potential investment attractiveness [14][17][18]. Company Recommendations - The report recommends focusing on innovative drug sectors and companies with improving performance in medical devices and upstream sectors, including companies like Hengrui Medicine, Changchun High-tech, and Mindray Medical [5][20].

Group 1 - The core management team of Fuli Instruments has been appointed, with Ms. Mu Yiping, the director and general manager of Nawei Technology, serving as the chairman of Fuli Instruments, and Dr. Yin Hongfeng appointed as the general manager, effective immediately [2][3]. - This adjustment aims to optimize corporate governance and operational efficiency, promoting high-quality and sustainable development [4]. - The company will continue to adhere to the philosophy of "sincerity for fortune, innovation for establishment," enhancing the competitiveness of its products and services [4].

Core Viewpoint - Nanwei Technology experienced a decline of 2.94% in stock price on October 9, with a trading volume of 199 million yuan, indicating a potential shift in investor sentiment [1] Financing Summary - On October 9, Nanwei Technology had a financing buy-in amount of 23.78 million yuan and a financing repayment of 29.94 million yuan, resulting in a net financing outflow of 6.16 million yuan [1] - The total financing and securities balance for Nanwei Technology reached 351 million yuan, with the financing balance accounting for 3.09% of the circulating market value, indicating a high level compared to the past year [1] - The company had a financing buy-in of 23.78 million yuan on the same day, with a financing balance of 350 million yuan, which is above the 80th percentile of the past year [1] Securities Lending Summary - On October 9, Nanwei Technology repaid 4,287 shares in securities lending and sold 3,700 shares, with a selling amount of 103,700 yuan based on the closing price [1] - The remaining securities lending volume was 37,400 shares, with a balance of 1.05 million yuan, also exceeding the 80th percentile of the past year [1] Company Overview - Nanwei Technology, established on October 22, 2007, and listed on June 23, 2021, specializes in the research, production, and sales of high-performance nano-microsphere materials for various applications, including biomedicine and diagnostics [2] - The company's revenue composition includes 57.62% from chromatography fillers and media, 19.72% from chromatography instruments and accessories, and 10.44% from liquid chromatography columns and sample pretreatment products [2] - As of June 30, 2025, Nanwei Technology reported a revenue of 414 million yuan, a year-on-year increase of 21.74%, and a net profit attributable to shareholders of 63.31 million yuan, reflecting a growth of 40.52% [2] Dividend Summary - Since its A-share listing, Nanwei Technology has distributed a total of 115 million yuan in dividends, with 86.84 million yuan distributed over the past three years [3] Shareholder Information - As of June 30, 2025, the number of shareholders for Nanwei Technology was 15,100, an increase of 2.29% from the previous period, with an average of 26,739 circulating shares per person, a decrease of 2.24% [2][3]

苏州纳微科技股份有限公司 简式权益变动报告书 上市公司名称：苏州纳微科技股份有限公司 股票上市地点：上海证券交易所 股票简称：纳微科技 股票代码：688690 信息披露义务人：陈荣华 住所：广东省深圳市福田区******** 通讯地址：广东省深圳市福田区******** 权益变动性质： 减少股份（减持）导致间接持股比例低于5% 签署日期：2025年9月29日 信息披露义务人声明 一、本报告书系信息披露义务人依据《中华人民共和国证券法》、《上市公 司收购管理办法》、《公开发行证券的公司信息披露内容与格式准则第 15 号- 权益变动报告书》及相关法律、法规和规范性文件编写。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违 反信息披露义务人章程或内部规则中的任何条款，或与之相冲突。 三、依据《中华人民共和国证券法》、《上市公司收购管理办法》及《公开 发行证券的公司信息披露内容与格式准则第 15 号—权益变动报告书》的规定， 本报告书已全面披露信息披露义务人在苏州纳微科技股份有限公司中拥有权益 的股份变动情况。 四、截至本报告书签署之日，除本报告书披露的信息外，信息披露义务人没 有通过任何其他方式 ...

证券代码：688690 证券简称：纳微科技 公告编号：2025-033 苏州纳微科技股份有限公司 关于持股 5%以上股东减持股份至 5%以下 的权益变动提示性公告 股东陈荣华保证向本公司提供的信息真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： 本次权益变动为苏州纳微科技股份有限公司（以下简称"公司"）间接 持股 5%股东陈荣华先生减持通过深圳市纳微科技有限公司（以下简称"深圳纳 微"）间接持有的部分公司股份所致，不触及要约收购。 本次权益变动后，信息披露义务人陈荣华先生通过深圳纳微以及苏州纳 合管理咨询有限公司（以下简称"苏州纳合"）间接合计持有公司股份 20,189,661 股，占公司总股本比例为 4.9997%，不再是公司间接持股 5%以上股份 股东。 | 身份证号码 | 440103197004****** | | --- | --- | | 住所 | 广东省深圳市福田区******** | | 是否取得其他国家或地 | 否 | | 区的居留权 | | （二）本次权益变动情况 2025年9月22日至2025年9 ...

Core Viewpoint - Suzhou Nawei Technology Co., Ltd. announced that indirect shareholder Chen Ronghua reduced his stake in the company, dropping below the 5% threshold, which will not affect the company's control or governance [1] Shareholder Changes - Chen Ronghua reduced his holdings by 37,000 shares from September 22 to 29, representing a change of 0.0092% [1] - After this reduction, Chen Ronghua, through Shenzhen Nawei and Suzhou Naha, holds a total of 20,189,661 shares, accounting for 4.9997% of the total share capital [1] - This change does not trigger a mandatory takeover bid and does not lead to changes in the company's controlling shareholder or actual controller [1] Future Plans - The reduction in holdings is part of a previously announced plan, which has not yet been fully executed as of the announcement date [1]

Market Overview - The chemical pharmaceutical sector increased by 0.39% on September 25, with Aosaikang leading the gains [1] - The Shanghai Composite Index closed at 3853.3, down 0.01%, while the Shenzhen Component Index closed at 13445.9, up 0.67% [1] Top Gainers in Chemical Pharmaceutical Sector - Aosaikang (002755) closed at 23.28, up 10.02% with a trading volume of 126,300 shares and a turnover of 286 million [1] - Guangshengtang (300436) closed at 121.57, up 9.37% with a trading volume of 235,500 shares and a turnover of 2.802 billion [1] - Naimi Technology (688690) closed at 27.99, up 6.02% with a trading volume of 94,700 shares and a turnover of 26.1 million [1] Top Losers in Chemical Pharmaceutical Sector - Mengke Pharmaceutical (688373) closed at 8.61, down 10.96% with a trading volume of 717,800 shares [2] - Borui Pharmaceutical (688166) closed at 66.41, down 8.40% with a trading volume of 239,000 shares [2] - Haichen Pharmaceutical (300584) closed at 57.90, down 5.95% with a trading volume of 103,000 shares [2] Capital Flow Analysis - The chemical pharmaceutical sector experienced a net outflow of 858 million from institutional investors, while retail investors saw a net inflow of 538 million [2] - The top stocks by net inflow from institutional investors included Guangshengtang with 325 million and Aosaikang with 97.5934 million [3] - Retail investors showed significant interest in Aosaikang, with a net outflow of 66.8017 million [3]